AbbVie Is a Dividend Growth Stock at a Bargain Price
AbbVie (NYSE: ABBV) reported fourth-quarter earnings on Friday that were above consensus and the company raised its guidance for 2020. The results suggested that there was life after Humira, its mainstay immunology product, which is the world's best-selling drug.
On a day when the market was down 1%, AbbVie's shares rose 5%. With the stock still trading at a discount to the market multiple and a dividend yield of 4.6%, AbbVie still has plenty of appeal for the long-term investor.
Image source: Getty Images.
Source Fool.com